DaVita Research Centers on Upstream CKD Management; Access & Equity during ASN's Kidney Week 2024

Rhea-AI Summary

DaVita Clinical Research (DCR) will present five research projects at ASN's Kidney Week 2024 in San Diego. The research focuses on improving racial equity in transplantation and clinical quality measures. Studies examine topics including: the impact of nephrologist visits on hospitalization rates, racial disparities in transplant processes among Hispanic dialysis patients, effects of heavy precipitation on dialysis treatment attendance, early indicators of ESKD transition in AKI-dialysis patients, and blood pressure thresholds in CKD patients. The presentations aim to enhance upstream CKD care management and promote health equity.

Positive

• Research initiatives demonstrate company's commitment to improving clinical outcomes
• Focus on addressing racial disparities could lead to market expansion in underserved populations
• Multiple research studies targeting key areas of kidney care management indicate strong R&D pipeline

Negative

• None.

News Market Reaction – DVA

-0.23%

1 alert

-0.23% News Effect

On the day this news was published, DVA declined 0.23%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DENVER and SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- DaVita Clinical Research (DCR), a leading innovator in kidney care research and wholly owned subsidiary of DaVita Inc., will present the results of five innovative research projects at the American Society of Nephrology (ASN)'s annual Kidney Week meeting, which is currently underway in San Diego, CA. With a focus on improving racial equity in transplantation and key measures of clinical quality such as hospitalizations, DCR works to tackle pressing issues in nephrology that affect diverse populations.  

The poster presentations include: 

• Nephrologist Visits Lower Rates of Hospitalization, Mortality, and ESKD Transition in CKD Patients
  Authors: Steph Karpinski, Michael O'Shea, Steven M. Brunelli
  
  
• Racial Disparities Exist in the Transplant Process among Hispanic Patients on Dialysis
  Authors: Adam G. Walker, Carey Colson, Danelle Radney, Unini Odama, Will Maixner, Francesca Tentori, Steven M. Brunelli
  
  
• Association of Heavy Precipitation with the In-Center Dialysis Treatment Absenteeism
  Authors: Adam G. Walker, Carey Colson, Scott Sibbel, Mesbah Ahmad, Francesca Tentori, Steven M. Brunelli
  
  
• Early Clinical Indicators of ESKD Transition or Renal Recovery in AKI-Dialysis Patients
  Authors: Scott Sibbel, Claire Ryan, Carey Colson, Cicely Gibson, Irina Goykhman, Francesca Tentori, Steven Brunelli
  
  
• Systolic Blood Pressure Threshold and Clinical Outcomes in CKD 4/5 Patients
  Authors: Jiacong Luo, Claire Ryan, Scott Sibbel, Carey Colson, Gilbert Marlowe, Michael O'Shea, Francesca Tentori, Steven M. Brunelli

"Kidney Week offers a unique opportunity to share groundbreaking research and foster meaningful dialogue within the nephrology community," stated Dr. Brunelli, vice president of health analytics and insights at DaVita. "Our findings support our unwavering commitment to enhancing upstream CKD care management, preventing kidney failure and promoting health equity. We look forward to engaging with attendees on these critical issues as DaVita strives to make a positive impact for patients."

ASN Kidney Week attendees can visit booth #821 at the San Diego Convention Center for more information about DaVita and DCR. Representatives from DCR are on-site at Kidney Week to discuss the research findings, DCR's focus and intentions behind their studies, and the opportunities for clinical research through the CKD and Rare Disease Network. 

Throughout the event, DaVita will share highlights and updates on social media. Follow @DaVitaDoc on X to learn more and engage with content from the meeting.

About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly-owned subsidiary of DaVita Inc., is the research arm of DaVita. DCR innovates through retrospective research aimed at improving clinical outcomes. DCR assists pharmaceutical and medical device companies in the design, recruitment and completion of clinical trials using its renal research site network. To learn more about DCR, visit DaVitaClinicalResearch.com.

About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of June 30, 2024, DaVita served approximately 265,100 patients at 3,124 outpatient dialysis centers, of which 2,672 centers were located in the United States and 452 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Media Contact:
DaVita Newsroom
newsroom@davita.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-research-centers-on-upstream-ckd-management-access--equity-during-asns-kidney-week-2024-302283815.html

SOURCE DaVita

FAQ

What research is DaVita (DVA) presenting at ASN Kidney Week 2024?

DaVita is presenting five research projects focusing on racial equity in transplantation and clinical quality measures, including studies on hospitalization rates, transplant disparities among Hispanic patients, and treatment absenteeism.

How is DaVita (DVA) addressing racial disparities in kidney care?

DaVita is conducting research on racial disparities in the transplant process among Hispanic dialysis patients and working to improve equity in transplantation access.

What are the main clinical quality measures being studied by DaVita (DVA) in 2024?

DaVita is studying hospitalization rates, ESKD transition, treatment absenteeism, blood pressure thresholds in CKD patients, and early clinical indicators in AKI-dialysis patients.